Eli Lilly to Acquire Merida Biosciences for Up to $2.875B
LLY Lilly(Eli) & Co
$1156.73 -1.52%
View chart & analysis → - 1Eli Lilly (LLY) has agreed to acquire Merida Biosciences for up to $2.875 billion in cash.
- 2The upfront payment is undisclosed, with the remainder tied to milestones; core asset MER511 is a Phase 1 treatment for Graves' disease and thyroid eye disease.
- 3The deal cap is roughly 12.5% of Q2 revenue of $22.974 billion, a platform bet that avoids full payment upfront.
This 3-line summary is compiled from the report below.
GuruFocus.com +1 View original ↗
오늘의 AI 픽 5종목, 무료로 전부 공개합니다숨기는 것 없이, 지난 픽의 성적표(S&P500 대비)까지 그대로 보여드립니다